利妥昔单抗治疗难治性结节病:单中心经验。

Q2 Medicine

Clinical and Molecular Allergy Pub Date : 2015-09-01 eCollection Date: 2015-01-01 DOI:10.1186/s12948-015-0025-9

Francesco Cinetto, Nicolò Compagno, Riccardo Scarpa, Giacomo Malipiero, Carlo Agostini

{"title":"利妥昔单抗治疗难治性结节病:单中心经验。","authors":"Francesco Cinetto, Nicolò Compagno, Riccardo Scarpa, Giacomo Malipiero, Carlo Agostini","doi":"10.1186/s12948-015-0025-9","DOIUrl":null,"url":null,"abstract":"Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic refractory disease. Provided that steroids represent the gold standard as a first line treatment, many immune suppressants drugs are currently used in the disease management. However, refractory disease is still a great challenge. Rituximab is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic autoimmune diseases. There are few case reports describing the successful use of Rituximab in refractory sarcoidosis with lung, eye, lymph nodes and skin involvement. In this paper we described three different case reports in which Rituximab has been used to treat refractory sarcoidosis and we reviewed the existing literature. ","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"13 1","pages":"19"},"PeriodicalIF":0.0000,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-015-0025-9","citationCount":"48","resultStr":"{\"title\":\"Rituximab in refractory sarcoidosis: a single centre experience.\",\"authors\":\"Francesco Cinetto, Nicolò Compagno, Riccardo Scarpa, Giacomo Malipiero, Carlo Agostini\",\"doi\":\"10.1186/s12948-015-0025-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic refractory disease. Provided that steroids represent the gold standard as a first line treatment, many immune suppressants drugs are currently used in the disease management. However, refractory disease is still a great challenge. Rituximab is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic autoimmune diseases. There are few case reports describing the successful use of Rituximab in refractory sarcoidosis with lung, eye, lymph nodes and skin involvement. In this paper we described three different case reports in which Rituximab has been used to treat refractory sarcoidosis and we reviewed the existing literature. \",\"PeriodicalId\":38753,\"journal\":{\"name\":\"Clinical and Molecular Allergy\",\"volume\":\"13 1\",\"pages\":\"19\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/s12948-015-0025-9\",\"citationCount\":\"48\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Molecular Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s12948-015-0025-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2015/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Molecular Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12948-015-0025-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 48

摘要

结节病是一种肉芽肿性疾病，其结局从自发缓解到慢性难治性疾病不等。鉴于类固醇作为一线治疗的黄金标准，目前许多免疫抑制药物用于疾病管理。然而，难治性疾病仍然是一个巨大的挑战。利妥昔单抗是一种抗cd20嵌合单克隆抗体，目前用于治疗B细胞恶性肿瘤和系统性自身免疫性疾病。很少有病例报告描述成功使用利妥昔单抗治疗难治性结节病伴肺、眼、淋巴结和皮肤受累。在本文中，我们描述了三个不同的病例报告，其中利妥昔单抗已被用于治疗难治性结节病，我们回顾了现有的文献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

$Rituximab in refractory sarcoidosis: a single centre experience.$

查看原文本刊更多论文

Rituximab in refractory sarcoidosis: a single centre experience.

Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic refractory disease. Provided that steroids represent the gold standard as a first line treatment, many immune suppressants drugs are currently used in the disease management. However, refractory disease is still a great challenge. Rituximab is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic autoimmune diseases. There are few case reports describing the successful use of Rituximab in refractory sarcoidosis with lung, eye, lymph nodes and skin involvement. In this paper we described three different case reports in which Rituximab has been used to treat refractory sarcoidosis and we reviewed the existing literature.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical and Molecular Allergy Medicine-Immunology and Allergy

CiteScore

8.20

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Clinical and Molecular Allergy is an open access, peer-reviewed, online journal that publishes research on human allergic and immunodeficient disease (immune deficiency not related to HIV infection/AIDS). The scope of the journal encompasses all aspects of the clinical, genetic, molecular and inflammatory aspects of allergic-respiratory (Type 1 hypersensitivity) and non-AIDS immunodeficiency disorders. However, studies of allergic/hypersensitive aspects of HIV infection/AIDS or drug desensitization protocols in AIDS are acceptable. At the basic science level, this includes original work and reviews on the genetic and molecular mechanisms underlying the inflammatory response.